Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 1789Neoplasms 1516Carcinoma, Non-Small-Cell Lung 1053Prostatic Neoplasms 965Colorectal Neoplasms 889Lung Neoplasms 809Pancreatic Neoplasms 583Carcinoma, Hepatocellular 543Leukemia, Myeloid, Acute 540Stomach Neoplasms 523Ovarian Neoplasms 513Neoplasm Metastasis 492Multiple Myeloma 491Recurrence 417Melanoma 390Squamous Cell Carcinoma of Head and Neck 374Uterine Cervical Neoplasms 366Brain Neoplasms 364Head and Neck Neoplasms 355Esophageal Neoplasms 320Precursor Cell Lymphoblastic Leukemia-Lymphoma 313Endometrial Neoplasms 311Lymphoma 309Triple Negative Breast Neoplasms 301Glioblastoma 298Rectal Neoplasms 284Urinary Bladder Neoplasms 268Sarcoma 266Hematologic Neoplasms 266Colonic Neoplasms 257

Interventions

repaglinide 1Tablets 1Rosuvastatin Calcium 1Metformin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × TP53 Y220C Mutation × Clear all
NCT07372625 2026-03-12

A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

PMV Pharmaceuticals, Inc

Phase 1 Recruiting
14 enrolled
Other solid neoplasm

TP53 Y220C Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡